AstraZeneca signs up to $1.7 billion R&D pact with China’s CSPC, marking second deal in six months
read at Endpoints ↗DealPositive
AstraZeneca announced a new research collaboration with Chinese partner CSPC, valued at up to $1.7 billion.
The agreement follows a previous large biobucks deal signed less than six months earlier, which was described as one of the biggest in industry history.
The partnership will focus on co‑development of drug candidates, extending AstraZeneca’s presence in the Chinese market and deepening its R&D ties with CSPC.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact”
read at Endpoints ↗84 words · retrieved Jul 2
comments(0)
5-min edit window · permanent after that